Publicacions
El coneixement generat a IrsiCaixa es comparteix amb la comunitat científica a través de la publicació d’articles a revistes científiques d’alt impacte.
![Imatge de Publicacions](/sites/default/files/styles/3_1_small/public/2022-11/Portada_publicacions-petita_0.jpg?h=c6980913&itok=oZMso2V6)
[Disseminated histoplasmosis and AIDS. Report of 4 cases].
Short-term anti-HIV activity of the combination of didanosine and hydroxyurea.
Plasma HIV-1 RNA as a predictor of the efficacy of adding zalcitabine to a previous regimen with zidovudine.
Switching from zidovudine to didanosine in patients with symptomatic HIV infection and disease progression. ddI Iberian Study Group.
[Bronchogenic carcinoma in patients with human immunodeficiency virus infection].
Quantitative HIV-1 RNA as a marker of clinical stability and survival in a cohort of 302 patients with a mean CD4 cell count of 300 x 10(6)/l.
Resistance-related mutations in the HIV-1 protease gene of patients treated for 1 year with the protease inhibitor ritonavir (ABT-538).
[The sexual transmission of zidovudine-resistant HIV-1 strains].
Long-term survivors of human immunodeficiency virus type 1 infection.
Lack of short-term efficacy of N-acetyl-L-cysteine in human immunodeficiency virus-positive patients with CD4 cell counts 250/mm3.